The Cost-Effectiveness of Financial Incentives to Achieve Heroin Abstinence in Individuals With Heroin Use Disorder Starting New Treatment Episodes: A Cluster Randomized Trial-Based Economic Evaluation

Value in Health - Tập 26 - Trang 658-665 - 2023
James Shearer1, Nicola Metrebian2, Tim Weaver3, Kimberley Goldsmith4, John Strang2, Stephen Pilling5, Luke Mitcheson6, Ed Day7, John Dunn8, Anthony Glasper9, Shabana Akhtar10, Jalpa Bajaria11, Vikki Charles2, Roopal Desai12, Farjana Haque13, Nicholas Little5, Hortencia McKechnie14, Franziska Mosler15, Julian Mutz2, Dilkushi Poovendran16
1King’s Health Economics, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, England, UK
2Addictions Department, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, England, UK
3Faculty of Health, Social Care and Education, Middlesex University, London, England, UK
4Department of Biostatistics & Health Informatics, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, England, UK
5University College London, London, England, UK
6South London and Maudsley NHS Foundation Trust, London, England, UK
7Institute for Mental Health, University of Birmingham, Birmingham, England, UK
8Camden and Islington NHS Foundation Trust, London, England, UK
9Sussex Partnership NHS Foundation Trust, London, England, UK
10Birmingham & Solihull Mental Health NHS Foundation Trust, London, England, UK
11CRN North West London, Imperial College Healthcare NHS Trust, London, England, UK
12ADAPT Lab, Research Department of Clinical, Educational and Health Psychology, University College London, London, England, UK
13National Addiction Centre, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, England, UK
14Imperial College London, London, England, UK
15Unit for Social and Community Psychiatry, Queen Mary University of London, London, England, UK
16Centre for Mental Health, Division of Brain Sciences, Imperial College London, London, England, UK

Tài liệu tham khảo

Jalali, 2020, The opioid crisis: a contextual, social-ecological framework, Health Res Policy Syst, 18, 87, 10.1186/s12961-020-00596-8 Gordon, 2006, The economic and social costs of class A drug use in England and Wales 2003/04 Godfrey Onuoha, 2021, Economic evaluations of pharmacologic treatment for opioid use disorder: a systematic literature review, Value Health, 24, 1068, 10.1016/j.jval.2020.12.023 Shearer, 2015, Economic evaluations of contingency management in illicit drug misuse programmes: a systematic review, Drug Alcohol Rev, 34, 289, 10.1111/dar.12240 Metrebian, 2021, Using a pragmatically adapted, low-cost, contingency management intervention to promote heroin abstinence in individuals undergoing treatment for heroin use disorder in UK drug services (PRAISE): a cluster randomised trial, BMJ open, 11, 10.1136/bmjopen-2020-046371 Metrebian, 2018, Positive Reinforcement targeting Abstinence in Substance misuse (PRAISe): cluster RCT & Process Evaluation of Contingency Management, Contemp Clin Trials, 71, 124, 10.1016/j.cct.2018.06.008 Byford, 2013, Cost-effectiveness of injectable opioid treatment v. oral methadone for chronic heroin addiction, Br J Psychiatry, 203, 341, 10.1192/bjp.bp.112.111583 Kind, 1996, The EuroQol instrument: an index of health related quality of life van der Zanden, 2006, Validity of the EQ-5D as a generic health outcome instrument in a heroin-dependent population, Drug Alcohol Depend, 82, 111, 10.1016/j.drugalcdep.2005.08.012 Dolan, 1997, Modeling valuations for EuroQol health states, Med Care, 35, 1095, 10.1097/00005650-199711000-00002 Richardson, 2004, Calculation of quality adjusted life years in the published literature: a review of methodology and transparency, Health Econ, 13, 1203, 10.1002/hec.901 Kessler, 2003, The World Health Organization Health and Work Performance Questionnaire (HPQ), J Occup Environ Med, 45, 156, 10.1097/01.jom.0000052967.43131.51 Curtis Drummond, 2015 Marsden, 2019, Effectiveness and cost-effectiveness of adjunctive personalised psychosocial intervention in treatment-resistant maintenance opioid agonist therapy: a pragmatic, open-label, randomised controlled trial, Lancet Psychiatry, 6, 391, 10.1016/S2215-0366(19)30097-5 Dubourg Brand Mihaylova, 2011, Review of statistical methods for analysing healthcare resources and costs, Health Econ, 20, 897, 10.1002/hec.1653 White, 2011, Multiple imputation using chained equations: issues and guidance for practice, Stat Med, 30, 377, 10.1002/sim.4067 Eddings, 2016 Schomaker, 2018, Bootstrap inference when using multiple imputation, Stat Med, 37, 2252, 10.1002/sim.7654 Barber, 2000, Analysis of cost data in randomized trials: an application of the non-parametric bootstrap, Stat Med, 19, 3219, 10.1002/1097-0258(20001215)19:23<3219::AID-SIM623>3.0.CO;2-P Fenwick, 2001, Representing uncertainty: the role of cost-effectiveness acceptability curves, Health Econ, 10, 779, 10.1002/hec.635 Robertson Stitzer, 2006, Editorial: contingency management and the addictions, Addiction, 101, 1536, 10.1111/j.1360-0443.2006.01644.x Volkov, 2021, The epidemic of fentanyl misuse and overdoses: challenges and strategies, World Psychiatry, 20, 195, 10.1002/wps.20846 Davis, 2016, A review of the literature on contingency management in the treatment of substance misuse disorders 2009-2014, Prev Med, 92, 36, 10.1016/j.ypmed.2016.08.008 Walker, 1983, Self-reported crime studies and the British crime survey, Howard J Crime Justice, 22, 168, 10.1111/j.1468-2311.1983.tb00482.x Darke, 1998, Self-report among injecting drug users: a review, Drug Alcohol Depend, 51, 253, 10.1016/S0376-8716(98)00028-3 El Alili, 2020, Taking the analysis of trial-based economic evaluations to the next level: the importance of accounting for clustering, Pharmacoeconomics, 38, 1247, 10.1007/s40273-020-00946-y
Thông tin
Thông tin xuất bản

Value in Health

Tập 26

658-665

Thông tin tác giả